DexCom, Inc. (DXCM)
NASDAQ: DXCM · Real-Time Price · USD
83.13
-2.33 (-2.73%)
Jul 11, 2025, 3:48 PM - Market open
DexCom Revenue
DexCom had revenue of $1.04B in the quarter ending March 31, 2025, with 12.49% growth. This brings the company's revenue in the last twelve months to $4.15B, up 9.11% year-over-year. In the year 2024, DexCom had annual revenue of $4.03B with 11.34% growth.
Revenue (ttm)
$4.15B
Revenue Growth
+9.11%
P/S Ratio
8.11
Revenue / Employee
$402,718
Employees
10,300
Market Cap
32.60B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4.03B | 410.70M | 11.34% |
Dec 31, 2023 | 3.62B | 712.50M | 24.49% |
Dec 31, 2022 | 2.91B | 461.30M | 18.84% |
Dec 31, 2021 | 2.45B | 521.80M | 27.08% |
Dec 31, 2020 | 1.93B | 450.70M | 30.54% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
DXCM News
- 1 day ago - Johnson Fistel Continues Investigation on Behalf of DexCom, Inc. Shareholders - GlobeNewsWire
- 3 days ago - The Best Growth Stocks to Buy - Kiplinger
- 10 days ago - Dexcom Schedules Second Quarter 2025 Earnings Release and Conference Call for July 30, 2025 at 4:30 p.m. Eastern Time. - Business Wire
- 23 days ago - Dexcom Unveils New Report on Type 2 Diabetes Management in the U.S. at ADA 2025 - Business Wire
- 5 weeks ago - Jefferies' high conviction US stocks for the summer: Nvidia among top picks - Invezz
- 2 months ago - Dexcom Announces Promotion of Jake Leach to the Expanded Role of President and COO - Business Wire
- 2 months ago - DexCom Q1 Earnings: Organic Revenue Growth Versus Cost Pressure - Seeking Alpha
- 2 months ago - DexCom: Growth Is Reaccelerating But Don't Ignore The Risks - Seeking Alpha